Akums Drugs Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 10 Aug 2026

Company page: Akums Drugs share price, financials & guidance record

Akums Drugs & Pharmaceuticals reported a strong Q1 FY27, with double-digit revenue and profit growth, primarily driven by its CDMO segment. Margins expanded significantly due to volume growth and improved API prices. The company also completed the acquisition of Oriflame India's manufacturing business to expand into skin care and wellness products. While certain marketing segments faced muted performance and the API business remained loss-making, management expressed confidence in their turnaround and growth strategies, supported by a robust cash-rich, debt-free balance sheet.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 18.1%, net profit up 0.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	328	337	329	332	309 −6%	369 +9%	338 +3%	392 +18%
Expenses	285	303	311	288	292	344	327	344
EBITDA	43	34	18	44	17 −60%	25 −26%	12 −33%	49 +11%
Margin	13%	10%	5%	13%	5%	7%	4%	12%
Other income	32	34	32	29	27	26	25	26
Interest	4	2	3	3	2	2	3	2
Depreciation	9	11	10	10	11	12	12	13
Profit before tax	62	55	37	60	31 −50%	36 −35%	22 −41%	59 −2%
Tax rate	18%	25%	26%	25%	25%	22%	30%	24%
Net profit	50	41	28	45	23 −54%	28 −32%	15 −46%	45 +0%
EPS	3.20	2.62	1.75	2.85	1.49	1.79	0.97	2.85

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls